A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Jul 2021 to 30 Jul 2021.
    • 02 May 2017 Planned primary completion date changed from 1 Apr 2021 to 27 Apr 2021.
    • 11 Oct 2016 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top